D'Angelo, S., Tirri, E., Giardino, A. M., De Rosa, T., Matucci‐Cerinic, M., Dagna, L., . . . Viapiana, O. (2024). Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study. International Journal of Rheumatic Diseases, 27(3), 1. https://doi.org/10.1111/1756-185X.15091
Chicago Style (17th ed.) CitationD'Angelo, Salvatore, et al. "Real‐world Effectiveness and Persistence of Golimumab as Second‐line Anti‐TNFα Drug in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis Patients in Italy: GO‐BEYOND, a 12‐month Prospective Observational Study." International Journal of Rheumatic Diseases 27, no. 3 (2024): 1. https://doi.org/10.1111/1756-185X.15091.
MLA (9th ed.) CitationD'Angelo, Salvatore, et al. "Real‐world Effectiveness and Persistence of Golimumab as Second‐line Anti‐TNFα Drug in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis Patients in Italy: GO‐BEYOND, a 12‐month Prospective Observational Study." International Journal of Rheumatic Diseases, vol. 27, no. 3, 2024, p. 1, https://doi.org/10.1111/1756-185X.15091.
